D
David E. Kleiner
Researcher at National Institutes of Health
Publications - 560
Citations - 60934
David E. Kleiner is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Liver biopsy & Medicine. The author has an hindex of 104, co-authored 495 publications receiving 50296 citations. Previous affiliations of David E. Kleiner include University of Virginia & Tufts University.
Papers
More filters
Journal ArticleDOI
The Delta-4 fibrosis score (D4FS): A novel fibrosis score in chronic hepatitis D
TL;DR: The D4FS is a clinically useful non-invasive fibrosis score that can accurately detect cirrhosis in patients with chronic HDV infection and should be performed to further validate clinical utility.
Journal ArticleDOI
Associations of Gender and a Proxy of female Menopausal status with Histological Features of Drug‐Induced Liver Injury
Ayako Suzuki,Huiman X. Barnhart,Jiezhun Gu,Herbert L. Bonkovsky,Herbert L. Bonkovsky,Hans L. Tillmann,Robert J. Fontana,David E. Kleiner +7 more
TL;DR: Assessment of associations of gender and female age 50 with histological features of liver injury in 212 adults enrolled in the Drug‐Induced Liver Injury Network (DILIN) registry found no significant associations with menopause.
Journal ArticleDOI
Assessment of monoethylglycinexylidide as measure of liver function for patients with chronic viral hepatitis
Ronald J. Elin,Michael W. Fried,Michael W. Fried,Maureen Sampson,Mark E. Ruddel,David E. Kleiner,Adrian M. DiBisceglie,Adrian M. DiBisceglie +7 more
TL;DR: It is concluded that assay of MEGX in patients with chronic viral hepatitis did not contribute to the assessment of liver function when compared with apparently healthy volunteers and traditional tests of liverfunction.
Journal ArticleDOI
Myxovirus-1 and protein kinase haplotypes and fibrosis in chronic hepatitis C virus.
Leland J. Yee,Yong Ming Tang,David E. Kleiner,Dai Wang,KyungAh Im,Abdus S. Wahed,Xiaomei Tong,Shannon L. Rhodes,Xiaowen Su,R. Margaret Whelan,Robert J. Fontana,Marc G. Ghany,Brian B. Borg,T. Jake Liang,Huiying Yang +14 more
TL;DR: In this paper, the authors evaluated the associations of myxovirus resistance-1 (Mx1), protein kinase (PKR), transforming growth factor-β1 (TGF-β), interleukin-10 (IL-10), and interferon-gamma (IFN-γ) genes with liver fibrosis in 374 treatment-naive patients with genotype-1 chronic HCV infection.
Journal ArticleDOI
Tremelimumab, a monoclonal antibody against CTLA-4, in combination with subtotal ablation (trans-catheter arterial chemoembolization [TACE], radiofrequency ablation [RFA] or cryoablation) in patients with hepatocellular carcinoma (HCC) and biliary tract carcinoma (BTC).
Austin G. Duffy,Oxana V. Makarova-Rusher,Drew Pratt,David E. Kleiner,Suzanne Fioravanti,Melissa Walker,Stephanie L. Carey,William D. Figg,Seth M. Steinberg,Victoria L. Anderson,Elliot Levy,Venkatesh Krishnasamy,Bradford J. Wood,Tim F. Greten +13 more
TL;DR: Transcatheter arterial chemoembolization (TACE), radiofrequency ablation (RFA) and cryoablation (CA) have been shown to induce a peripheral immune response which may enhance the effect of anti-CTLA4 treatment in patients with advanced HCC.